Fierce Healthcare

JULY 9, 2023

The federal government will pay eligible hospitals in the 340B program $9 billion to offset payment cuts the Supreme Court ruled unlawful last year. | The federal government will pay eligible hospitals in the 340B program $9 billion to offset payment cuts the Supreme Court ruled unlawful last year.

Hospitals 116

Hospitals 116

pharmaphorum

JULY 9, 2023

Novartis will appeal Entresto patent setback Phil.

98

98

Pharmaceutical Technology

JULY 9, 2023

In this issue: Artificial intelligence tools for patients, EU funding for British biotech, analytics for continuous manufacturing, Apple’s play for the metaverse.

52

52

Med Ed 101

JULY 9, 2023

Patients use numerous supplements that contain vitamins. I outline my top 5 vitamin drug interactions in this post and how they may impact patient care. Vitamin K and Warfarin The first vitamin drug interaction you could probably guess. Vitamin K intake affects warfarin and ultimately a patient’s INR. Consistent intake is recommended when taking warfarin. […] The post Top 5 Vitamin Drug Interactions appeared first on Med Ed 101.

Patient Care 52

Patient Care 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

BioPharm

JULY 9, 2023

Discovery why evaluating a CMO’s internal processes, facilities, capacity, capabilities, and communication is key to successful ophthalmic scale up and manufacturing.

Communication 40

Communication 40

BioPharm

JULY 9, 2023

There has been a Growing concern among regulators driving a need for awareness for manufacturers to understand the risk associated with nitrosamines in pharmaceutical and biopharmaceutical products. In this session of Changing the Conversation with SGS Live, we tackled a variety of aspects of this important issue from the risk associated with nitrosamine contamination to discovery and mitigation of nitrosamine impurities.

40

40